Pricing Log in Create free account

Adaptimmune Therapeutics PLC (ADAPY) vs Clovis Oncology, Inc. (CLVSQ)

Adaptimmune Therapeutics PLC and Clovis Oncology, Inc. are both Biotechnology companies. Adaptimmune Therapeutics PLC and Clovis Oncology, Inc. are of similar size ($14.6M and $14.2M). Clovis Oncology, Inc. grew revenue faster over the last twelve months: −14.8% against −54.0%. Clovis Oncology, Inc. has the higher net margin (−189.4% vs −262.5%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Clovis Oncology, Inc. leads on 11 and Adaptimmune Therapeutics PLC on 5.

Valuation

Metric ADAPY CLVSQ Biotechnology median
P/E n/m n/m 8.50
P/S 0.12 0.10 9.71
P/B n/m n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 0.12 3.08 9.21
Earnings yield (2,166.67%) (2,033.33%) (33.15%)
Free cash flow yield (2,380.45%) (1,412.40%) (25.50%)

Profitability

Metric ADAPY CLVSQ Biotechnology median
Gross margin 94.81% 72.21% 65.16%
Operating margin (427.75%) (155.38%) 0.00%
Net margin (262.46%) (189.37%) 0.00%
Free cash flow margin (288.20%) (132.19%) 0.00%
Return on equity (1,349.52%) 78.31% (56.36%)
Return on assets 0.00% (58.94%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ADAPY CLVSQ Biotechnology median
Revenue growth (TTM) (53.99%) (14.78%) 6.02%
EPS growth (last fiscal year) 142.86% 47.72% 30.26%
Revenue growth, 5-year CAGR 8.40% 352.98% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ADAPY CLVSQ Biotechnology median
Debt to equity (0.36) (1.05) 0.00
Current ratio 1.52 0.14 4.72
Net debt to EBITDA 0.47 (2.16) 0.96

Dividend

Metric ADAPY CLVSQ Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ADAPY CLVSQ Biotechnology median
Market cap 14.55m 14.23m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack